Muscle invasive bladder cancer
Conditions
Interventions
PA-MSHA group:After radical cystectomy, spray PA-MSHA intraperitoneally before abdominal closure
Control group:PA-MSHA was not used during operation
Sponsors
Lanzhou University Second Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Non-metastatic muscle-invasive bladder cancer with pathologic staging of pT1-4aN0-2M0; (2) The pathologic type was urothelial carcinoma; (3) RC and PLND were performed, as well as arbitrary urinary diversion (Maniz II, neobladder, Bricker or cutaneous ureterostomy); (4) Spray 10ml PA-MSHA in the operation area before abdominal closure; (5) Complete medical records were available.
Exclusion criteria
Exclusion criteria: (1) Neoadjuvant chemotherapy, immuno-target treatment, radiotherapy or concurrent chemoradiotherapy was received before surgery; (2) Radical cystectomy after receiving bladder preservation treatment, e.g., cTURBt (conventional transurethral resection of bladder tumor) combination with EBRT (external beam radiation therapy, TURBT (transurethral resection of bladder tumor) or partial cystectomy combination with chemotherapy or chemoradiotherapy; (3) Perioperative death due to operative complications, such as myocardial infarction, acute pulmonary embolism, intestinal fistula, hemorrhea etc..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival;Cancer-specific survival;Incidence of chyle leaks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative adverse reactions and complications;Incidence of adverse events within 3 months after surgery;Long-term complications;Total drainage volume within 3 days after surgery and drainage tube removal time;Postoperative hospital stay; | — |
Countries
China
Contacts
Public ContactWang Zhiping
Lanzhou University Second Hospital
Outcome results
None listed